Anzeige
Mehr »
Montag, 08.06.2026 - Börsentäglich über 12.000 News
Explorer vor Durchbruch? 2 Kilometer Anomalie - trifft diese Aktie jetzt den Jackpot?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 659990 | ISIN: DE0006599905 | Ticker-Symbol: MRK
Xetra
08.06.26 | 15:54
137,05 Euro
-1,76 % -2,45
1-Jahres-Chart
MERCK KGAA Chart 1 Jahr
5-Tage-Chart
MERCK KGAA 5-Tage-Chart
RealtimeGeldBriefZeit
137,45137,5516:12
137,45137,5516:12
GlobeNewswire (Europe)
234 Leser
Artikel bewerten:
(1)

Merck Appoints New Heads of Discovery Solutions and Strategy & Business Development for Life Science Business Sector

Darmstadt, Germany, June 08, 2026 (GLOBE NEWSWIRE) --

  • Clara Sattler de Sousa e Brito appointed Head of Discovery Solutions, bringing extensive international leadership experience across healthcare, medtech and the chemical industry
  • Robert Machinek appointed Head of Strategy & Business Development, bringing deep expertise in life science strategy, M&A and digital transformation
  • Appointments strengthen the Life Science leadership team as the business advances its strategy and innovation agenda

Merck, a leading science and technology company, today announced the appointments of Clara Sattler de Sousa e Brito as Head of Discovery Solutions and Robert Machinek as Head of Strategy & Business Development for the company's Life Science business. Sattler de Sousa e Brito will assume her role in the third quarter of 2026 and Machinek assumes his role effective immediately.

"The life science industry is at a pivotal moment, with customers working to accelerate discovery and development while navigating more complex science, more digital workflows and rising expectations for speed, reliability and impact," said Jean-Charles Wirth, Member of the Executive Board of Merck and CEO Life Science. "Our strategy is focused on empowering customers to succeed in this dynamic environment through trusted products, innovative solutions and strong execution. Clara and Robert bring the leadership experience, customer focus and strategic mindset needed to advance that strategy, and position Life Science for its next phase of growth."

As Head of Discovery Solutions, Sattler de Sousa e Brito will lead the business unit focused on supporting research and early-stage discovery with digital tools, trusted products and innovative technologies across biology, chemistry and analytical workflows.

Sattler de Sousa e Brito joins Merck from Philips International BV, where she served as EVP and Market Leader Europe. Previously, she held international senior roles at Siemens Healthineers and The Linde Group, with P&L responsibility across healthcare, medical technology and chemical industries. She brings extensive experience in commercial execution, business development and digital transformation, with a focus on driving growth and innovation through customer-centric leadership and high-performing teams.

As Head of Strategy & Business Development, Machinek will lead the organization responsible for shaping and executing the Life Science strategy, guiding organic and inorganic growth, ensuring strategic alignment across business units and regions, and overseeing the ERP business program. In this role, he will help advance the company's strategic priorities and support the continued evolution of the Life Science business. Machinek served as interim head of the organization prior to his appointment to the role.

Before joining Merck, Machinek was a Partner at McKinsey & Company, where he led strategic life science and healthcare engagements across North America, Europe and Asia. His expertise spans strategic growth, major ERP transformations, M&A, digital initiatives and global operations optimization. Machinek holds a PhD in Physics from the University of Oxford and a B.Sc. in Physics from RWTH Aachen University.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2025, Merck generated sales of € 21.1 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Attachment

  • Merck Appoints New Heads of Discovery Solutions and Strategy & BD for Life Science


Jenny Wuestner Merck +4915114543158 jenny.wuestner@merckgroup.com

© 2026 GlobeNewswire (Europe)
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.